J Nephropathol. 2012;1(3): 126-129. doi: 10.5812/nephropathol.8107
PMID: 24475402        PMCID: PMC3886158

Editorial

Lipoprotein(a), type 2 diabetes and nephropathy; the mystery continues


Cited by CrossRef: 7


1- Nasri R. Renoprotective effects of metformin. DARU. 2013;21(1):36 [Crossref]
2- Nasri H, Nasri P, Baradaran A, Abedi-Gheshlaghi Z, Rafieian-Kopaei M. World Kidney Day 2016: Awareness for Saving Kidneys. Shiraz E-Med J. 2015;16(9-10) [Crossref]
3- Baradaran A. Commentary on: effect of vitamin D on insulin resistance and anthropometric parameters in type 2 diabetes; a randomized double-blind clinical trial. DARU. 2013;21(1):19 [Crossref]
4- Nasri H. Re Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes. Diabetes & Metabolism. 2013;39(4):375 [Crossref]
5- Rafieian Kopaei M, Baradaran A. Protective Effects of Metformin on Renal Tubular Cells. Iran Red Crescent Med J. 2014;16(9) [Crossref]
6- Zhang S, Xu H, Yu X, Wu Y, Sui D. Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes. 2017;14(1):383 [Crossref]
7- Savira M, Savira R, Syahputra M. Association of serum uric acid level and blood pressure in type 2 diabetes mellitus. IOP Conf Ser: Earth Environ Sci. 2018;125:012169 [Crossref]